Standing Out in the Crowd - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Standing Out in the Crowd
Supplier differentiation is increasingly important in the highly competitive arena of pharmaceutical outsourcing.


Pharmaceutical Technology
Volume 35, pp. s6

Amidst these conditions, we explore how contract-service providers can achieve competitive advantage by looking at the drivers that influence customers' perceptions of contract-service providers overall and in certain segments (see "Customer Drivers Influencing Supplier Differentiation").

As the level and complexity of outsourcing increases, bio/pharmaceutical companies speak about how project management is a valued competency of a contract-service provider not only in meeting its obligations, but also in working with other service providers. To illustrate, we offer a case study of a cross-functional supplier integration model (see "Achieving Cross-Functional Supplier Integration: A Case-Study Analysis").

Part of the task in developing a sustainable competitive advantage is to understand not only what customers value now, but what they will in the future. As bio/pharmaceutical companies begin to adapt quality by design (QbD) in their drug-development and manufacturing efforts, will competency in QbD become equally important for contract-service providers? We gain perspectives from both sides of this issue. Senior executives from Pfizer offer insight on the company's experience with QbD (see "A Pharma Manufacturer’s View of Quality by Design"), and an industry roundtable of technology and contract-service providers share their views on the influence of QbD on the outsourced relationship (see "Evaluating QbD's Impact on the Outsourced Relationship").

Also in this issue, Avantor shares its experience in a pilot of the shared audit process of Rx–360, the international pharmaceutical supply-chain consortium (see "Rx-360 Completes Pilot Audit of Manufacturing Facility: An Industry Case Study from Avantor"). We also share best practices in collaborative planning (see "Outsourced Manufacturing Operations") and technology transfer (see "Managing Technology Transfer: Developing a Complete CMC Package for an In-Licensed Product").

Patricia Van Anrum is a senior editor of Pharmaceutical Technology,
and a co-editor of this special issue.

References

1. M.E. Porter, Competitive Advantage: Creating and Sustaining Superior Performance (Free Press, 1st ed., New York, 1985).

2. M.E. Porter, Competitive Strategy: Techniques for Analyzing Industries and Competitors (Free Press, 1st ed., New York, 1980).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here